Several classes of medication lower A1c, with reductions ranging from about 0.5% to over 2% depending on the drug, the dose, and how high your A1c is when you start. Metformin remains the standard first-line treatment for type 2 diabetes, but newer medications, particularly GLP-1 receptor agonists and dual agonists, now deliver the largest A1c drops seen in clinical trials.
How much any medication lowers your A1c depends heavily on where you’re starting. Someone with an A1c of 9% will typically see a bigger numerical drop than someone starting at 7.5%, even on the same drug. Here’s how the major medication classes compare.
Metformin: The Standard Starting Point
Metformin is the most widely prescribed diabetes medication in the world, and for good reason. It lowers A1c by up to 1.5% at maximum doses, carries almost no risk of causing low blood sugar on its own, and is weight-neutral, meaning it won’t make you gain or lose significant weight. It works by reducing the amount of sugar your liver releases into your bloodstream and by helping your cells respond better to insulin.
Most people with a new type 2 diabetes diagnosis will start on metformin unless they have a specific reason not to take it, such as severe kidney problems. It’s inexpensive, available as a generic, and has decades of safety data behind it. The most common side effects are digestive: nausea, bloating, and diarrhea, which often improve after the first few weeks or with an extended-release version.
GLP-1 and Dual Agonists: The Strongest A1c Reductions
The most powerful A1c-lowering medications currently available are the injectable GLP-1 receptor agonists and the newer dual GLP-1/GIP agonists. These drugs mimic gut hormones that trigger insulin release after meals, slow stomach emptying, and reduce appetite.
Semaglutide (sold as Ozempic for diabetes) lowered A1c by 1.86% in a major head-to-head trial called SURPASS-2. Tirzepatide (Mounjaro), which targets two gut hormone receptors instead of one, performed even better in the same trial, reducing A1c by 2.01% to 2.30% depending on the dose. Both medications also cause significant weight loss. In that trial, people on tirzepatide lost 7.6 to 11.2 kg (roughly 17 to 25 pounds), while semaglutide produced about 5.7 kg (12.5 pounds) of weight loss. A later trial found tirzepatide led to about 20% body weight loss compared to about 14% for semaglutide.
This combination of strong glucose control and weight reduction makes these drugs particularly effective for people who are both overweight and struggling with high blood sugar. The risk of low blood sugar is negligible when used without insulin or sulfonylureas. The main downsides are cost (these remain expensive brand-name medications), nausea during the first weeks of treatment, and the need for weekly injections.
SGLT2 Inhibitors: Moderate A1c Lowering With Extra Benefits
SGLT2 inhibitors work through a completely different mechanism. They block your kidneys from reabsorbing sugar, so you excrete excess glucose in your urine. This typically lowers A1c by 0.4% to 0.7% when used alone, and by 0.5% to 0.9% when added to metformin. In some monotherapy trials, reductions reached up to 1.2%.
The A1c drop is more modest than what you’d get from a GLP-1 agonist, but these medications carry meaningful benefits beyond blood sugar. They promote weight loss of about 2 to 3 kg and have shown strong evidence of protecting the heart and kidneys. For someone with type 2 diabetes who also has heart failure or kidney disease, an SGLT2 inhibitor is often prioritized regardless of A1c level. The main side effects include urinary tract infections and genital yeast infections, both related to the higher sugar content in urine.
DPP-4 Inhibitors: A Gentler Option
DPP-4 inhibitors are oral pills that work by extending the activity of natural gut hormones involved in blood sugar regulation. They lower A1c by about 0.5% to 0.7% on average, though the effect varies by specific drug. A large meta-analysis of 98 clinical trials found that the range ran from about 0.55% to 0.88% depending on the specific medication, and that people with higher starting A1c levels tended to see bigger reductions. At a baseline A1c of 8%, for example, one of these drugs could reduce it by roughly 0.6% to 1.0% depending on fasting glucose levels.
These medications don’t cause low blood sugar on their own, don’t affect weight, and are generally very well tolerated. They’re a reasonable choice when someone needs a modest A1c reduction on top of metformin but can’t tolerate or access the stronger injectable options.
Sulfonylureas: Effective but With Trade-Offs
Sulfonylureas have been around for decades and remain widely prescribed, particularly where cost is a concern. They stimulate your pancreas to release more insulin regardless of your blood sugar level, which is why they carry a real risk of causing low blood sugar (hypoglycemia). They lower A1c by 0.7% to 1.3%, putting them in the same general ballpark as metformin in terms of potency.
The trade-offs are meaningful. Beyond hypoglycemia risk, sulfonylureas tend to cause weight gain of 1.5 to 2.5 kg. Their effectiveness also tends to fade over time as the insulin-producing cells in the pancreas wear down. They remain a practical option for people who need affordable A1c reduction and don’t have access to newer drug classes.
Insulin: The Most Flexible Option
Insulin is the oldest diabetes treatment and still the most flexible. It can lower A1c by 0.9% to 1.2% or more, and there’s no ceiling on its effectiveness because the dose can be adjusted upward. In pooled data from 15 clinical trials, people starting basal (long-acting) insulin with an average A1c of 8.8% saw it drop by 1.4% within 12 weeks, with a small additional decrease by 24 weeks.
Insulin is typically added when oral medications and other injectables aren’t bringing A1c to target, or when someone is diagnosed with very high blood sugar levels that need to come down quickly. The downsides are the risk of hypoglycemia (particularly with older insulin types), weight gain of up to 4 to 5 kg with some regimens, and the need for injections and blood sugar monitoring. Newer long-acting insulin formulations cause less hypoglycemia and less weight gain than older versions.
Other Medication Classes
A few other drug classes play smaller roles. Thiazolidinediones (pioglitazone being the most commonly used) lower A1c by about 0.8% to 0.9% and don’t cause hypoglycemia, but they cause weight gain of 2.5 to 5 kg and have been linked to fluid retention and bone fracture risk. Meglitinides work similarly to sulfonylureas but are shorter-acting, lowering A1c by 0.7% to 1.1% with a somewhat lower hypoglycemia risk. Alpha-glucosidase inhibitors, which slow carbohydrate digestion, reduce A1c by about 0.7% to 0.8% but often cause gas and bloating that limit their use.
How Lifestyle Changes Compare
Intensive lifestyle changes, meaning structured diet and exercise programs, can lower A1c by about 0.4% over six months based on data from Harvard-affiliated research. That’s meaningful but modest compared to most medications. In that study, people who made significant lifestyle changes saw their A1c drop from 6.6% to 6.2%, though some of the improvement faded by the 12-month mark.
Lifestyle changes work best as a foundation under medication, not as a replacement. The combination of a healthier diet, regular physical activity, and even one well-chosen medication produces better long-term results than either approach alone. For someone whose A1c is only slightly above target, lifestyle changes might be enough. For someone at 8% or above, medication is almost always necessary to reach a safe range.
Choosing the Right Medication
The “best” A1c-lowering medication depends on more than just how many percentage points it can shave off. Your starting A1c, body weight, kidney function, heart health, insurance coverage, and tolerance for injections all factor in. Here’s a simplified way to think about the major options:
- Biggest A1c reduction: Tirzepatide (up to 2.3%) and semaglutide (up to 1.86%), both injectables
- Best first-line oral option: Metformin (up to 1.5%), cheap and well-studied
- Best for heart or kidney protection: SGLT2 inhibitors (0.4% to 1.2% A1c reduction plus organ-protective effects)
- Best for weight loss alongside A1c control: Tirzepatide or semaglutide
- Lowest cost: Metformin and sulfonylureas, both available as inexpensive generics
- Most adjustable: Insulin, with no upper limit on A1c reduction
Most people with type 2 diabetes end up on more than one medication over time, because the condition tends to progress. Starting with metformin and adding a second drug when needed is the most common pattern, though some guidelines now recommend starting with a GLP-1 agonist or SGLT2 inhibitor alongside metformin for people with existing heart disease or high cardiovascular risk.